Vanda Pharmaceuticals, Inc. :VNDA-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017

Vanda Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017.

We analyze the earnings along side the following peers of Vanda Pharmaceuticals, Inc. – Paratek Pharmaceuticals Inc, Novartis AG Sponsored ADR, Eli Lilly and Company, Pfizer Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., Pernix Therapeutics Holdings, Inc. and Titan Pharmaceuticals, Inc. (PRTK-US, NVS-US, LLY-US, PFE-US, BMY-US, MRK-US, PTX-US and TTNP-US) that have also reported for this period.

Highlights

  • Summary numbers: Revenues of USD 41.34 million, Net Earnings of USD -4.55 million.
  • Gross margins widened from 74.19% to 88.01% compared to the same period last year, operating (EBITDA) margins now -10.04% from 6.52%.
  • Year-on-year change in operating cash flow of 74.70% is about the same as the change in earnings, likely no significant movement in accruals or reserves.
  • Narrowing of operating margins contributed to decline in earnings.

The table below shows the preliminary results and recent trends for key metrics such as revenues and net income growth:

2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30
Relevant Numbers (Quarterly)
Revenues (mil) 41.34 42.06 37.42 38.24 38.48
Revenue Growth (%YOY) 7.42 16.73 12.49 20.08 35.77
Earnings (mil) -4.55 -1.53 -7.65 -0.6 -0.43
Earnings Growth (%YOY) -958.14 66.78 38.14 95.92 95.46
Net Margin (%) -11.01 -3.65 -20.43 -1.58 -1.12
EPS -0.1 -0.03 -0.17 -0.01 -0.01
Return on Equity (%) -3.47 -1.18 -5.89 -0.46 -0.34
Return on Assets (%) -8.74 -2.95 -14.73 -1.15 -0.84

Access our Ratings and Scores for Vanda Pharmaceuticals, Inc.

Market Share Versus Profits

Revenues History
Earnings History

VNDA-US’s change in revenue this period compared to the same period last year of 7.42% is almost the same as its change in earnings, and is about average among the announced results thus far in its peer group, suggesting that VNDA-US is holding onto its market share. Also, for comparison purposes, revenues changed by -1.71% and earnings by -196.61% compared to the immediate last period.

Revenues Growth Versus Earnings Growth

Quadrant label definitions. Hover to know more

Leader, Earnings Focus, Laggard, Revenues Focus

Earnings Growth Analysis

The company’s earnings declined year-on-year largely because of the increases in operating costs. Its operating margins (EBITDA margins) went from 6.52% to -10.04%. This decline in earnings would have been worse except for the fact that the company showed improvement in gross margins, from 74.19% to 88.01%. For comparison, gross margins were 88.20% and EBITDA margins -2.83% in the immediate last period.

Gross Margin Versus EBITDA Margin

Quadrant label definitions. Hover to know more

Differentiated; Low Cost, Commodity; Low Cost, Commodity; High Cost, Differentiated; High Cost

Gross Margin Trend

Companies sometimes sacrifice improvements in revenues and margins in order to extend friendlier terms to customers and vendors. Capital Cube probes for such activity by comparing the changes in gross margins with any changes in working capital. If the gross margins improved without a worsening of working capital, it is possible that the company’s performance is a result of truly delivering in the marketplace and not simply an accounting prop-up using the balance sheet.

Gross Margin History
Working Capital Days History

VNDA-US’s improvement in gross margin has been accompanied by an improvement in its balance sheet as well. This suggests that gross margin improvements are likely from operating decisions and not accounting gimmicks. Its working capital days are now 217.24 days compared to 269.98 days for the same period last year.

Gross Margin Versus Working Capital Days

Quadrant label definitions. Hover to know more

Customer Financed, Cash Starved, Supplier Financed, Cash Rich

Cash Versus Earnings – Sustainable Performance?

It is important to examine a company�s cash versus earnings numbers to gauge whether its performance is sustainable.

VNDA-US’s change in operating cash flow of 74.70% compared to the same period last year is about the same as its change in earnings this period. Additionally, this change in operating cash flow is about average among its peer group. This suggests that the company did not use accruals or reserves to manage earnings this period, and that, all else being equal, the earnings number is sustainable.

Operating Cash Flow Growth Versus Earnings Growth

Quadrant label definitions. Hover to know more

Cash Flow based Earnings, Likely Non-cash Earnings, Low Cash Flow Base, Likely Undeclared Earnings

Margins

The company’s decline in earnings has been influenced by the following factors: (1) Decline in operating margins (EBIT margins) from -1.70% to -11.91% and (2) one-time items that contributed to a decrease in pretax margins from -1.12% to -10.95%

EBIT Margin Versus PreTax Margin

Quadrant label definitions. Hover to know more

Operation driven Earnings, One-time Favorables, Low Earnings Base, One-time Unfavorables
EBIT Margin History
PreTax Margin History

Access our Ratings and Scores for Vanda Pharmaceuticals, Inc.

Company Profile

Vanda Pharmaceuticals, Inc. is a global biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve the lives of patients. It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

CapitalCube does not own any shares in the stocks mentioned and focuses solely on providing unique fundamental research and analysis on approximately 50,000 stocks and ETFs globally. Try any of our analysis, screener or portfolio premium services free for 7 days. To get a quick preview of our services, check out our free quick summary analysis of VNDA-US.

Disclaimer

The information presented in this report has been obtained from sources deemed to be reliable, but AnalytixInsight does not make any representation about the accuracy, completeness, or timeliness of this information. This report was produced by AnalytixInsight for informational purposes only and nothing contained herein should be construed as an offer to buy or sell or as a solicitation of an offer to buy or sell any security or derivative instrument. This report is current only as of the date that it was published and the opinions, estimates, ratings and other information may change without notice or publication. Past performance is no guarantee of future results. Prior to making an investment or other financial decision, please consult with your financial, legal and tax advisors. AnalytixInsight shall not be liable for any party’s use of this report. AnalytixInsight is not a broker-dealer and does not buy, sell, maintain a position, or make a market in any security referred to herein. One of the principal tenets for us at AnalytixInsight is that the best person to handle your finances is you. By your use of our services or by reading any of our reports, you’re agreeing that you bear responsibility for your own investment research and investment decisions. You also agree that AnalytixInsight, its directors, its employees, and its agents will not be liable for any investment decision made or action taken by you and others based on news, information, opinion, or any other material generated by us and/or published through our services. For a complete copy of our disclaimer, please visit our website www.analytixinsight.com.